STEPHEN REALE: Open Payments
NPI 1396846572 · VAN NUYS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,122 in 47 payments from 15 companies in 2025. Trend: 2023 $462 · 2024 $932 · 2025 $1,122
Food & beverage: $1,122
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $135 |
| Amgen Inc. | 7 | $124 |
| Vanda Pharmaceuticals Inc. | 4 | $114 |
| Lilly USA, LLC | 4 | $114 |
| SANOFI-AVENTIS U.S. LLC | 4 | $95 |
| AstraZeneca Pharmaceuticals LP | 4 | $91 |
| Phathom Pharmaceuticals, Inc. | 3 | $88 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $79 |
| Merck Sharp & Dohme LLC | 3 | $74 |
| ABBVIE INC. | 4 | $69 |
Products named: CAPLYTA, FANAPT, OTEZLA, TZIELD, VOQUEZNA, JARDIANCE, GARDASIL 9, VRAYLAR.
Industry payments across CA — which companies pay providers there.
